«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

29卷

期数:

2023年06期

页码:

604-608,621

栏目:

基础医学

出版日期:

2023-11-20

文章信息/Info

Title:

Study of the mechanism of oriental wormwood in the treatment of benign prostatic hyperplasia based on network pharmacology

文章编号:

1006-8147(2023) 06-0604-06

作者:

李晓石¹; 李世宾¹; 刘芬²

（1.新乡市中心医院，新乡医学院第四临床学院泌尿外科，新乡453000；2.新乡市中心医院，新乡医学院第四临床学院病理科，新乡453000）

Author(s):

LI Xiao-shi¹; LI Shi-bin¹; LIU Fen²

（1.Department of Urology，Xinxiang Central Hospital，The Fourth Clinical College of Xinxiang Medical College，Xinxiang 453000，China；2.Department of Pathology，Xinxiang Central Hospital，The Fourth Clinical College of Xinxiang Medical College，Xinxiang 453000，China）

关键词:

茵陈; 良性前列腺增生症; 网络药理学

Keywords:

oriental wormwood; benign prostatic hyperplasia; network pharmacology

分类号:

R697.3

DOI:

-

文献标志码:

A

摘要:

目的：探索使用网络药理学方法和动物实验研究中药茵陈治疗良性前列腺增生症（BPH）的作用机制。方法：通过TCMSP数据库筛选出茵陈有效成分及其靶点，经uniprot统一靶点简写；GeneCards、OMIM及GisGeNET数据库在线检索BPH的疾病靶点。在venny 2.1网站筛选出交集靶点并将交集靶点在线做“蛋白-蛋白”网络分析和GO、京都基因与基因组百科全书（KEGG）富集分析。使用Cytoscape制作“成分-靶点-通路”网络图。建立BPH大鼠模型，使用茵陈药液灌胃治疗，采用酶联免疫方法检测靶蛋白表达。结果：茵陈中有12个有效成分，这些有效成分通过干预67个靶点调节多个分子通路，从而治疗BPH。槲皮素、茵陈色酮、β-谷甾醇、芫花素、茵陈黄酮、异鼠李素等是核心成分，肿瘤蛋白p53（TP53）、丝/苏氨酸蛋白激酶（AKT）1、表皮生长因子受体（EGFR）、JUN、白细胞介素-6（IL-6）、肿瘤坏死因子（TNF）、血管内皮生长因子A（VEGFA）是核心靶点。GO分析结果显示，生物过程主要涉及细胞对激素反应和对脂质的反应等，细胞组分包含转录调节复合物、膜筏、质膜筏等，分子功能包含DNA结合转录因子结合、核受体活性和激酶调节活性等。KEGG分析结果显示磷脂酰肌醇3 激酶（PI3K）-AKT、缺氧诱导因子-1（HIF-1）、IL-17、TNF、丝裂原活化蛋白激酶（MAPK）、EGFR、P53等信号通路与茵陈治疗BPH相关。动物实验结果显示，经茵陈治疗后前列腺重量减轻，血清TP53蛋白表达增加，血清AKT1、EGFR、JUN、IL-6、TNF、VEGFA等蛋白表达减少（均P<0.000 1）。结论：茵陈作为治疗BPH的中药可以通过多种通路参与调控疾病靶点，具有良好的治疗效果和广泛的作用机制。

Abstract:

Objective： To study the mechanism of the oriental wormwood treating benign prostatic hyperplasia（BPH） by using network pharmacology and animal experiments. Methods：First，the active constituents and targets were screened out by TCMSP database，and then uniprot was used to simplify the target. GeneCards，OMIM and GisGeNET databases were used to search disease targets of BPH online. The intersection targets were screened on venny 2.1 website，and the intersection targets were analyzed online for "protein-protein" network analysis and GO and Kyoto Encyclopedia of Genes and Genomes（KEGG） enrichment analysis. Then，the Cytoscape was used to create a Composition-Target-Pathway network diagram. Finally，the rat models of BPH were established and treated by intragastric administration with oriental wormwood. The expression of targets protein was detected by ELISA. Results：There were 12 active components of oriental wormwood in the treatment of BPH by intervening 67 targets and regulating multiple molecular pathways. The core components were Quercetin，Capillarisin，β-sitosterol，genkwanin，wormwood flavone，isorhamnetin and so on. Tumor protein p53（TP53），silk/threonine protein kinase（AKT）1，epidermal growth factor receptor（EGFR），JUN，interleukin-6（IL-6），tumor necrosis factor（TNF），vascular endothelial growth factor A（VEGFA） were the core targets. GO analysis results showed that biological processes mainly involved cell responses to hormones and lipids. Cellular components included transcriptional regulatory complexes，membrane rafts，plasma membrane rafts. Molecular functions included DNA binding，transcription factor binding，nuclear receptor activity and kinase regulatory activity. The results of the KEGG analysis showed that phosphatidylinositol 3 kinase （PI3K）-AKT，hypoxia-inducible factor-1（HIF-1），IL-17，TNF，mitogen-activated protein kinase（MAPK），EGFR，P53 and other signaling pathways are related to the treatment of BPH by oriental wormwood. The results of animal experiments showed that the weight of the prostate decreased，the expression of serum TP53 protein increased and the protein expression of serum AKT1，EGFR，JUN，IL6，TNF and VEGFA decreased after the treatment of oriental wormwood（all P<0.000 1）. Conclusion： As a traditional Chinese medicine for the treatment of BPH oriental wormwood can participate in the regulation of disease targets through various pathways，and has good therapeutic effect and extensive mechanisms.

参考文献/References:

[1] KAPLAN S A. Benign prostatic hyperplasia[J]. J Urol，2021，205（5）：1490-1492.
[2] MANOV J J，MOHAN P P，KAVA B，et al. Benign prostatic hyperplasia：a brief overview of pathogenesis，diagnosis，and current state of therapy[J]. Tech Vasc Interv Radiol，2020，23（3）：100687.
[3] EID B G，ABDEL-NAIM A B. Piceatannol attenuates testosterone-induced benign prostatic hyperplasia in rats by modulation of Nrf2/HO-1/NFκB axis[J]. Front Pharmacol，2020，11：614897.
[4] STROPE S A. Evidence-based guidelines in lower urinary tract symptoms secondary to benign prostatic hyperplasia and variation in care[J]. Curr Opin Urol，2018，28（3）：262-266.
[5] REN R M，KOU M，LAN X X. Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia：a meta analysis[J]. Chin Med J（Engl），2010，123（2）：234-238.
[6] 郭俊，杜冠潮，赵丰，等. 基于VOSviewer与CiteSpace的良性前列腺增生中医药研究现状与趋势的知识图谱分析[J].世界科学技术-中医药现代化，2021，23（6）：1902-1908.
[7] 李杰，魏永进，宋光烨，等. 前列腺疾病的中医体质研究进展[J].中国当代医药，2021，28（4）：23-26.
[8] 黄丽平，许远航，邓敏贞，等. 茵陈的化学成分、药理作用机制与临床应用研究进展[J].天然产物研究与开发，2021，33（4）：676-690.
[9] 贾照志. 茵陈蒿的化学成分，药理作用及临床应用进展[J].牡丹江医学院学报，2010，31（3）：87-89.
[10] 李慧峰，孟霜，王鑫鑫，等. 基于网络药理学及实验验证探讨复方茴芹颗粒治疗前列腺增生的作用机制[J].中成药，2022，44（9）：3041-3047.
[11] GONG Y M，WANG X，LIU S，et al. Simvastatin inhibits prostatic hyperplasia in rats with metabolic syndrome[J].Int Urol Nephrol，2022，54（9）：2125-2131.
[12] ROSSI A，BRAGONZI A，MEDEDE M，et al. β-sitosterol ameliorates inflammation and pseudomonas aeruginosa lung infection in a mouse model[J]. J Cyst Fibros，2023，22（1）：156-160.
[13] WANG X，ZHU J，YAN H，et al. Kaempferol inhibits benign prostatic hyperplasia by resisting the action of androgen[J]. Eur J Pharmacol，2021，907：174251.
[14] KHAN S，SHEHZAD O，CHUN J，et al. Anti-hyperalgesic and anti-allodynic activities of capillarisin via suppression of inflammatory signaling in animal model[J]. J Ethnopharmacol，2014，152（3）：478-486.
[15] JANG E，KIM S Y，LEE N R，et al. Evaluation of antitumor activity of artemisia capillaris extract against hepatocellular carcinoma through the inhibition of IL-6/STAT3 signaling axis[J].Oncol Rep，2017，37（1）：526-532.
[16] 胡黄金，雷利娟，郑靓怡，等. 升降通癃方中空栓对前列腺增生大鼠模型的影响[J].环球中医药，2022，15（9）：1523-1528.
[17] VICKMAN R E，AARON-BROOKS L，ZHANG R，et al. TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease[J]. Nat Commun，2022，13（1）：2133.
[18] LEE H H，PARK C，JEONG J W，et al. Apoptosis induction of human prostate carcinoma cells by cordycepin through reactive oxygen species mediated mitochondrial death pathway[J]. Int J Oncol，2013，42（3）：1036-1044.

相似文献/References:

备注/Memo

备注/Memo:

作者简介 李晓石（1984-），男，主治医师，硕士，研究方向：泌尿系疾病的诊疗等；通信作者：刘芬，E-mail：fenliutj2011@163.com。

常用功能

更新日期/Last Update: 2023-12-01